Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27872681 | 0.98 | MAPT (0.37) | MAPTSMN1; SMN2CHRM2CHRM4CHRM3 | |
| SCHEMBL11328517 | 0.94 | MAPT (0.37) | MAPTSMN1; SMN2CHRM2CHRM4CHRM3 | |
| SCHEMBL11359743 | 0.92 | SMN1; SMN2 (0.38) | MAPTSMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL17694210 | 0.92 | SMN1; SMN2 (0.38) | MAPTSMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL11359740 | 0.92 | SMN1; SMN2 (0.38) | MAPTSMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL4022810 | 0.92 | SMN1; SMN2 (0.38) | MAPTSMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL4022813 | 0.92 | SMN1; SMN2 (0.38) | MAPTSMN1; SMN2RAB9ANPC1MEN1 | |
| SCHEMBL6641149 | 0.88 | — | — | |
| SCHEMBL15324962 | 0.88 | — | — | |
| SCHEMBL7723415 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111432851-B | Use of volatile components to limit or eliminate perception of malodor | 弗门尼舍有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-111432851-A | Use of volatile ingredients to limit or eliminate perception of malodour | 弗门尼舍有限公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-3116857-B1 | CONSTRAINED TRICYCLIC SULFONAMIDES | ICAHN SCHOOL MED MOUNT SINAI (US) | 2019-02-06 | — | — | EP | disclosed |
| WO-2018210828-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2018-11-22 | — | — | WO | disclosed |
| CN-107922396-A | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | 建新公司 | 2018-04-17 | — | — | CN | disclosed |
| US-9937180-B2 | Constrained tricyclic sulfonamides | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-04-10 | — | — | US | disclosed |
| US-9937186-B2 | Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-04-10 | — | — | US | disclosed |
| US-9937180-B2 | Constrained tricyclic sulfonamides | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-04-10 | — | — | US | disclosed |
| US-9937180-B2 | Constrained tricyclic sulfonamides | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-04-10 | — | — | US | disclosed |
| EP-3116860-B1 | SULFONAMIDES DERIVED FROM TRICYCLYL-2-AMINOCYCLOALKANOLS AS ANTICANCER AGENTS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2014115078-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-07-31 | — | — | WO | disclosed |
| US-8367859-B2 | Cyclohexane 1,4 carboxylates | Amyris, Inc. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110288310-A1 | CYCLOHEXANE 1,4 CARBOXYLATES | DRATHS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| CN-101959872-A | Method for producing epoxy compound | SHOWA DENKO KK | 2011-01-26 | — | — | CN | disclosed |
| US-5876898-A | MULTICOLOR RECORDING OF HIGH CONTRAST | MITSUBISHI PAPER MILLS LIMITED (JP) | 1999-03-02 | — | — | US | disclosed |
| EP-0754564-A2 | Heat sensitive recording material and recording method using the same | MITSUBISHI PAPER MILLS, LTD. (JP) | 1997-01-22 | — | — | EP | disclosed |
| WO-1991013616-A1 | NOVEL HMG-CoA REDUCTASE INHIBITORS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1991-09-19 | — | — | WO | disclosed |
| US-4996234-A | Anticholesterol agents | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-02-26 | — | — | US | disclosed |
| US-4900754-A | ANTICHOLESTEROL AGENTS | RORER PHARMACEUTICAL CORP. (US) | 1990-02-13 | — | — | US | disclosed |
| US-4249015-A | Preparation of organic acids and/or esters | SHELL OIL COMPANY (US) | 1981-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288310-A1 | CYCLOHEXANE 1,4 CARBOXYLATES | CNR2, CBR1, CCR4 | MAPT 3871/4885SMN1; SMN2 4108/4885CHRM2 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.